Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

miR-210 and miR-152 as Biomarkers by Liquid Biopsy in Invasive Ductal Carcinoma

Texto completo
Autor(es):
Lopes, Beatriz C. [1] ; Braga, Cristine Z. [2] ; Ventura, Fabricio V. [2] ; de Oliveira, Jessica G. [2] ; Kato-Junior, Edson M. [2] ; Bordin-Junior, Newton A. [3] ; Zuccari, Debora A. P. C. [1, 2, 4]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] Inst Biosci Letters & Exact Sci IBILCE, BR-15054000 Sao Jose Do Rio Preto, SP - Brazil
[2] Fac Med Sao Jose do Rio Preto FAMERP, BR-15054000 Sao Jose Do Rio Preto, SP - Brazil
[3] Hosp Base Sao Jose do Rio Preto, BR-15090000 Sao Jose Do Rio Preto, SP - Brazil
[4] Lab Mol Invest Canc LIMC, Ave Brigadeiro Faria Lima 5416, BR-15090000 Sao Jose Do Rio Preto, SP - Brazil
Número total de Afiliações: 4
Tipo de documento: Artigo Científico
Fonte: JOURNAL OF PERSONALIZED MEDICINE; v. 11, n. 1 JAN 2021.
Citações Web of Science: 0
Resumo

Detecting circulating microRNAs (miRNAs; miRs) by means of liquid biopsy is an important tool for the early diagnosis and prognosis of breast cancer (BC). We aimed to identify and validate miR-210 and miR-152 as non-invasive circulating biomarkers, for the diagnosis and staging of BC patients, confirming their involvement in tumor angiogenesis. Methods: RT-qPCR was performed and MiRNA expression analysis was obtained from plasma and fragments of BC and benign breast condition (BBC) women patients, plus healthy subjects. Additionally, the immunohistochemistry technique was carried out to analyze the expression of target proteins. Results: Tumor fragments showed increased expression of oncomiR-210 and decreased expression of miR-152 tumoral suppressor. Both miRNAs were increased in plasma samples from BC patients. The receiver operating characteristic (ROC) curve analysis revealed that only the expression of oncomiR-210 in tissue samples and only the expression of the miR-152 suppressor in plasma have the appropriate sensitivity and specificity for use as differential biomarkers between early/intermediate and advanced stages of BC patients. In addition, there was an increase in the expression of hypoxia-inducible factor 1-alpha (HIF-1 alpha), insulin-like growth factor 1 receptor (IGF-1R), and vascular endothelial growth factor (VEGF) in BC patients. On the contrary, a decrease in Von Hippel-Lindau (VHL) protein expression was observed. Conclusions: This study showed that increased levels of miR-210 and decreased levels of miR152, in addition to the expressions of their target proteins, could indicate, respectively, the oncogenic and tumor suppressive role of these miRNAs in fragments. Both miRNAs are potential diagnostic biomarkers for BC by liquid biopsy. In addition, miR-152 proved to be a promising biomarker for disease staging. (AU)

Processo FAPESP: 17/15006-5 - Marcadores tumorais em biópsia líquida: estudo dos mecanismos de resistência por bloqueio do reparo de DNA: análise comparativa
Beneficiário:Debora Aparecida Pires de Campos Zuccari
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 17/11807-3 - Assinatura de microRNAs circulantes no diagnóstico e prognóstico de mulheres com câncer de mama
Beneficiário:Beatriz Camargo Lopes
Linha de fomento: Bolsas no Brasil - Mestrado